FlurbiprofenA potent inhibitor of Cox-1 and Cox-2

Flurbiprofen (CAS 5104-49-4)

Flurbiprofen | CAS 5104-49-4 is rated 5.0 out of 5 by 1.
  • y_2019, m_9, d_18, h_23
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_202158, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 27ms
  • REVIEWS, PRODUCT
Synonym: Ansaid
Application: A potent inhibitor of Cox-1 and Cox-2
CAS Number: 5104-49-4
Purity: ≥98%
Molecular Weight: 244.3
Molecular Formula: C15H13FO2
Supplemental Information: This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

Flurbiprofen is a mixture of S(+) and R(-) enantiomers. Flurbiprofen is a cell-permeable, non-steroidal anti-inflammatory (NSAID) agent that acts as a potent inhibitor of Cox-1 (cyclooxygenase-1) and Cox-2 (cyclooxygenase-2) (IC50 = 5 nM for LPS-induced Cox in human peripheral blood cells). The S(+) enantiomer is reported to be more potent as a Cox-2 inhibitor than the R(-) enantiomer. Flurbiprofen suppresses iNOS expression in RAW 264.7 macrophages. It reduces Aβ loads and Congo Red staining in APP+PS1 transgenic mice.


References

1. Karmali, R A., et al., 1986. Antitumor activity in a rat mammary adenocarcinoma: the effect of cyclooxygenase inhibitors and immunization against prostaglandin E2. Prostaglandins, leukotrienes, and medicine. 23(1): 11-4. PMID: 3090559
2. Karmali, R A., et al., 1985. Antitumor activity in a rat mammary adenocarcinoma: the effect of cyclooxygenase inhibitors and immunization against prostaglandin E2. Prostaglandins, leukotrienes, and medicine. 20(3): 283-6. PMID: 3937158
3. Curnock, A P., et al., 1997. Potencies of leflunomide and HR325 as inhibitors of prostaglandin endoperoxide H synthase-1 and -2: comparison with nonsteroidal anti-inflammatory drugs. The Journal of pharmacology and experimental therapeutics. 282(1): 339-47. PMID: 9223572
4. Wechter, W J., et al., 1997. R-flurbiprofen chemoprevention and treatment of intestinal adenomas in the APC(Min)/+ mouse model: implications for prophylaxis and treatment of colon cancer. Cancer research. 57(19): 4316-24. PMID: 9331093
5. Riendeau, D., et al., 1997. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays. Canadian journal of physiology and pharmacology. 75(9): 1088-95. PMID: 9365818
6. Klabunde, T., et al., 2000. Rational design of potent human transthyretin amyloid disease inhibitors. Nature structural biology. 7(4): 312-21. PMID: 10742177
7. Range, S P., et al., 2000. Selectivity of cyclo-oxygenase inhibitors in human pulmonary epithelial and smooth muscle cells. The European respiratory journal. 15(4): 751-6. PMID: 10780769
8. van Haeringen, N J., et al., 2000. Constitutive cyclooxygenase-1 and induced cyclooxygenase-2 in isolated human iris inhibited by S(+) flurbiprofen. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. 16(4): 353-61. PMID: 10977131
9. Jantzen, Paul T., et al., 2002. Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. 22(6): 2246-54. PMID: 11896164

Physical State :
Solid
Solubility :
Soluble in DMSO (50 mg/ml), methanol (50 mg/ml), ethanol (~100 mg/ml), DMF (~100 mg/ml), and buffers of ionic strength ≥0.1 M and pH ≥7.4 (~5 mg/ml). Insoluble in water.
Storage :
Store at room temperature
Melting Point :
110-112° C (lit.)
Boiling Point :
376.23° C at 760 mmHg (Predicted)
Density :
1.2 g/cm3 (Predicted)
Refractive Index :
n20D 1.57 (Predicted)
IC50 :
LPS-induced COX: IC50 = 5 nM (human peripheral blood cells); COX-2: IC50 = 0.51 µM (human); COX-1: IC50 = 0.04 µM (human)
pK Values :
pKa: 4.14
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
WGK Germany :
3
RTECS :
DU8341000
PubChem CID :
3394
Merck Index :
14: 4199
MDL Number :
MFCD00079303
EC Number :
225-827-6
SMILES :
CC(C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 160ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from A slight A slight, but noticeable decrease in cyclin A protein expression observed by WB in Caco-2 cells post treatment with flurbiprofin. -SCBT QC
Date published: 2015-01-30
  • y_2019, m_9, d_18, h_23
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_202158, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 24ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.